Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Delpazolid (LCB01-0371)
NCT03492996Phase 1Completed
- Sponsor
- LigaChem Biosciences
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of delpazolid in Tuberculosis (TB) and Gram-positive bacterial infection, sponsored by LigaChem Biosciences. Primary endpoint: Absorption, Metabolism, Excretion of LCB01-0371 at 8 days. Started Jun 2020; status: completed.
02
Drugs
delpazolid
03
Conditions
Tuberculosis (TB)Gram-positive bacterial infection
Beyond the preview
Go deeper on NCT03492996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492996.